As Regulatory Strategist, Ms. Aggarwal will be a member of Neuronoff’s executive team and will drive the company’s regulatory approval, first market access and subsequent commercialization efforts over the course of the next 12 months. ‍

“We are very fortunate to welcome Shobha Aggarwal to the Neuronoff team,” said Manfred Franke, CEO of Neuronoff. “Her extensive experience in leadership roles in product development, verification and validation testing, regulatory processes and commercialization of active implantable medical devices, as well as her strategic insights, make her an invaluable member of Neuronoff. Her team leadership and regulatory insights have enabled great strides over the past months as we were preparing clinical trial and regulatory submissions for what we believe will permit greater user experiences for patients, physicians and providers alike. Her hands-on experiences and results-driven mindset will enable us to make 2024 the most impactful year for Neuronoff to date.”

Ms. Aggarwal is an industry veteran with a management role at Advanced Bionics, and executive management roles at SetPoint Medical and Presidio Medical. She has extensive experience in navigating active medical implantable devices, such as cochlear implants, vagus nerve stimulators and pain treatment in the spinal column, from concept to global markets.

Shobha Aggarwal: "I look forward to shaping the company's operations to achieve regulatory approval and first market access next year, and contributing to Neuronoff’s mission to help the millions of patients impacted by chronic pain who have no elegant solution to choose from today.”